Vis enkel innførsel

dc.contributor.authorde Jonge, Lindaen_US
dc.contributor.authorGarne, Esteren_US
dc.contributor.authorGini, Rosaen_US
dc.contributor.authorJordan, Susan E.en_US
dc.contributor.authorKlungsøyr, Karien_US
dc.contributor.authorLoane, Mariaen_US
dc.contributor.authorNeville, Amanda J.en_US
dc.contributor.authorPierini, Annaen_US
dc.contributor.authorPuccini, Auroraen_US
dc.contributor.authorThayer, Daniel S.en_US
dc.contributor.authorTucker, Daviden_US
dc.contributor.authorVinkel Hansen, Anneen_US
dc.contributor.authorBakker, Marian K.en_US
dc.PublishedDrug Safety 2015, 38:1083-1093eng
dc.description.abstractIntroduction Research on associations between medication use during pregnancy and congenital anomalies is significative for assessing the safe use of a medicine in pregnancy. Congenital anomaly (CA) registries do not have optimal information on medicine exposure, in contrast to prescription databases. Linkage of prescription databases to the CA registries is a potentially effective method of obtaining accurate information on medicine use in pregnancies and the risk of congenital anomalies. Methods We linked data from primary care and prescription databases to five European Surveillance of Congenital Anomalies (EUROCAT) CA registries. The linkage was evaluated by looking at linkage rate, characteristics of linked and non-linked cases, first trimester exposure rates for six groups of medicines according to the prescription data and information on medication use registered in the CA databases, and agreement of exposure. Results Of the 52,619 cases registered in the CA databases, 26,552 could be linked. The linkage rate varied between registries over time and by type of birth. The first trimester exposure rates and the agreements between the databases varied for the different medicine groups. Information on anti-epileptic drugs and insulins and analogue medicine use recorded by CA registries was of good quality. For selective serotonin reuptake inhibitors, anti-asthmatics, antibacterials for systemic use, and gonadotropins and other ovulation stimulants, the recorded information was less complete. Conclusion Linkage of primary care or prescription databases to CA registries improved the quality of information on maternal use of medicines in pregnancy, especially for medicine groups that are less fully registered in CA registries.en_US
dc.rightsAttribution CC BYeng
dc.subjectMaternal Medication Useeng
dc.titleImproving information on maternal medication use by linking prescription data to congenital anomaly registers: a EUROmediCAT studyen_US
dc.typeJournal article
dc.rights.holderCopyright The Author(s) 2015
dc.subject.nsiVDP::Medisinske fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728
dc.subject.nsiVDP::Midical sciences: 700::Basic medical, dental and veterinary sciences: 710::Pharmacology: 728
dc.subject.nsiVDP::Medisinske Fag: 700en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution CC BY
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution CC BY